The HAI diagnostics market size is projected to cross $4.3 billion by 2023, growing at a CAGR of 7.6% between 2017-2023.
The growth in the market will be led by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities.
In terms of product, the HAI diagnostics market is segmented into reagents & consumables and instruments. The reagents & consumables occupied the larger share in the market in 2016 and are expected to maintain the same trend throughout the forecast period. This is attributable to specificity of the reagents providing the accurate results with the target substance in the sample. In medical laboratories, reagents play an important role in diagnostic testing assays of infectious diseases.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample
The European HAI diagnostics market is projected to grow at a steady pace during 2017-2023, to cross $1.2 billion by 2023. According to the International Trade Administration (ITA), there is growth in the market, with the major companies such as Roche Diagnostics Limited, Abbott Laboratories, and others investing more in the R&D of the innovative diagnostics products to remain competitive in this field. Along with it, the growth of the hospital acquired diagnostics market in Europe is also characterized by the increase in geriatric population and high incidence of hospital acquired infections.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market
Technologically advanced products aid by offering accurate and reliable results with low turnaround time. Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field. For instance, Roche diagnostics, in 2017, launched cobas Liat PCR system with four assays, which also include 20-minute real-time PCR nucleic acid test to detect Clostridium difficile. The company also launched cobas HPV for using on cobas 6800/8800 system for cervical cancer screening, 2017. Cobas 6800/8800 system is a two integrated and fully automated molecular testing system for blood and plasma donor screening. Qiagen N.V., in 2017, launched ipsogen JAK2 RGQ PCR Kit for detection of blood cancer, ipsogen portfolios common, and rare leukemia types.
Some of the key players operating in the HAI diagnostics market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
The growth in the market will be led by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities.
In terms of product, the HAI diagnostics market is segmented into reagents & consumables and instruments. The reagents & consumables occupied the larger share in the market in 2016 and are expected to maintain the same trend throughout the forecast period. This is attributable to specificity of the reagents providing the accurate results with the target substance in the sample. In medical laboratories, reagents play an important role in diagnostic testing assays of infectious diseases.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample
The European HAI diagnostics market is projected to grow at a steady pace during 2017-2023, to cross $1.2 billion by 2023. According to the International Trade Administration (ITA), there is growth in the market, with the major companies such as Roche Diagnostics Limited, Abbott Laboratories, and others investing more in the R&D of the innovative diagnostics products to remain competitive in this field. Along with it, the growth of the hospital acquired diagnostics market in Europe is also characterized by the increase in geriatric population and high incidence of hospital acquired infections.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market
Technologically advanced products aid by offering accurate and reliable results with low turnaround time. Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field. For instance, Roche diagnostics, in 2017, launched cobas Liat PCR system with four assays, which also include 20-minute real-time PCR nucleic acid test to detect Clostridium difficile. The company also launched cobas HPV for using on cobas 6800/8800 system for cervical cancer screening, 2017. Cobas 6800/8800 system is a two integrated and fully automated molecular testing system for blood and plasma donor screening. Qiagen N.V., in 2017, launched ipsogen JAK2 RGQ PCR Kit for detection of blood cancer, ipsogen portfolios common, and rare leukemia types.
Some of the key players operating in the HAI diagnostics market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com